Galderma Group AG Registered Shares
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
CHF 45.00 | Spphvs | Gwtczzqs |
Galderma's Diversified Dermatology Portfolio and Drug Pipeline Support Positive Outlook
Business Strategy and Outlook
Galderma is a pure-play dermatology company, with a leadership position in the self-care segment of the market, with more than 90% of total sales paid by consumers out of pocket. Its long-term revenue growth is supported by changing consumer behavior and perception around skin health and appearance. The company deploys an omnichannel go-to-market strategy, supported by a specialized, high-touch salesforce of over 1,900 employees reaching more than 110,000 healthcare professionals. This is complemented by a leading presence at dermatology congresses and an emphasis on educational, training, and loyalty programs to reinforce physician entrenchment.